Experimental treatment for sickle cell disease success
Posted: 20 June 2019 | Victoria Rees (Drug Target Review) | 1 comment
Researchers announce positive pre-clinical results for two sickle cell disease treatment strategies.
A leading genome editing company has announced successful results from a study to assess two different CRISPR genome editing strategies. One study targeted BCL11A erythroid enhancer (BC11Ae) and the other targeted the beta-globin locus for the treatment of sickle cell disease and beta-thalassemia. The pre-clinical results establish a possible way to develop therapies for sickle cell disease.
In the study, mice were given an infusion of human CD34+ cells which had been edited either at the BCL11Ae or at the beta-globin locus. In vivo-derived erythroid cells from BC11Ae-edited CD34+ hematopoietic stem/progenitor cells then reduced total indels and increased non-productive indels. Compared to other tested lineages, this reaction has not been observed in beta-globin locus editing.
Further optimisation of nuclease and guide RNA combinations led to foetal haemoglobin expression of approximately 40 percent in the beta-globin locus-edited erythroid cells.
Biomarkers aren’t just supporting drug discovery – they’re driving it
FREE market report
From smarter trials to faster insights, this report unpacks the science, strategy and real-world impact behind the next generation of precision therapies.
What you’ll unlock:
- How biomarkers are guiding dose selection and early efficacy decisions in complex trials
- Why multi-omics, liquid biopsy and digital tools are redefining the discovery process
- What makes lab data regulatory-ready and why alignment matters from day one
Explore how biomarkers are shaping early drug development
Access the full report – it’s free!
Editas Medicine, the company who led the research, has initiated IND-enabling activities for EDIT-301. This is an experimental CRISPR medicine designed to durably treat sickle cell disease and beta-thalassemia by editing the beta-globin locus.
“We are encouraged by these pre-clinical results demonstrating cells edited at the beta-globin locus repopulated all lineages of the blood system including, importantly, the red blood cell precursors and the high percentage of foetal haemoglobin expression. Editing at this site continues to meet our pre-clinical goals for making a medicine including robust, long-term induction of foetal haemoglobin and maintenance of normal hematopoietic stem/progenitor cell function,” said Charles Albright, Chief Scientific Officer at Editas Medicine.
“Our programme is on track towards the clinic, and we have started our IND-enabling activities as we look to develop a best-in-class medicine for the treatment of sickle cell disease and beta-thalassemia.”
Related topics
CRISPR, Drug Targets, Genome Editing, In Vivo
Related conditions
beta-thalassemia, Sickle cell disease (SCD)
Related organisations
Editas Medicine
Related people
Charles Albright
With hemoglobin disorders showing a vast occurrence around the globe, especially in the Sub-Saharan and South-east Asian regions, this is a significant development for combating diseases such as sickle-cell anemia and thalassemia. With organizations and Governments working together to make breakthroughs regarding hemoglobinopathy, it is no wonder that a report by Grand View Research has pegged the sector at around 12.5 billion USD, as crucial developments continue to be made in this sector.